Associations between cigarette smoking and mitochondrial DNA abnormalities in buccal cells by Tan, Duanjun et al.
Carcinogenesis vol.29 no.6 pp.1170–1177, 2008
doi:10.1093/carcin/bgn034
Advance Access publication February 14, 2008
Associations between cigarette smoking and mitochondrial DNA abnormalities in
buccal cells
Duanjun Tan, David S.Goerlitz, Ramona G.Dumitrescu,
Dingfen Han, Franc xoise Seillier-Moiseiwitsch, Stephanie
M.Spernak, Roy Anthony Orden, Jinguo Chen, Radoslav
Goldman and Peter G.Shields 
Cancer Genetics and Epidemiology Program, Lombardi Comprehensive
Cancer Center, Georgetown University Medical Center, Washington, DC
20057, USA
 To whom correspondence should be addressed. Lombardi Comprehensive
Cancer Center, Georgetown University Medical Center, 3800 Reservoir Road
Northwest, LL Level, Room 150, PO Box 571465, Washington, DC 20057,
USA. Tel: þ1 202 687 0003; Fax: þ1 202 687 0004;
Email: pgs2@georgetown.edu
DNA alterations in mitochondria are believed to play a role in
carcinogenesis and are found in smoking-related cancers. We
sought to replicate earlier ﬁndings for the association of smoking
with increased mitochondrial DNA (mtDNA) content in buccal
cells and further hypothesized that there would be an increased
number of somatic mtDNA mutations in smokers. Buccal cells
and blood lymphocytes were studied from 42 healthy smokers
and 30 non-smokers. Temporal temperature gradient electropho-
resis screening and sequencing was used to identify mtDNA mu-
tations. The relative mtDNA content was determined by real-time
polymerase chain reaction. Assuming that mtDNAin lymphocytes
represents the inherited sequence, it was found that 31% of smok-
ers harbored at least one somatic mtDNA mutation in buccal cells
with a total of 39 point mutations and 8 short deletions/insertions.
In contrast, only 23% of non-smokers possessed mutations with
a total of 10 point mutations and no insertions/deletions detected.
mtDNA somatic mutation density was higher in smokers
(0.68/10 000 bp per person) than in non-smokers (0.2/10 000 bp
per person). There was a statistically signiﬁcant difference in the
pattern of homoplasmy and heteroplasmy mutation changes be-
tween smokers and non-smokers. Whereas non-smokers had the
most mutations in D-loop region (70%), smokers had mutations in
both messenger RNA encoding gene (36%) and D-loop region
(49%). The mean ratio of buccal cells to lymphocytes of mtDNA
content in smokers was increased (2.81) when comparedwith non-
smokers (0.46). These results indicate that cigarette smoke expo-
sure affects mtDNA in buccal cells of smokers. Additional studies
are needed to determine if mitochondrial mutation assays provide
new or complementary information for estimating cigarette
smoke exposure at the cellular level or as a cancer risk biomarker.
Introduction
Mitochondria are intracellular organelles that produce adenosine tri-
phosphate by the coupling of oxidative phosphorylation to respiration,
providing a major source of energy to the cell. They are the major
source of endogenous reactive oxygen species (ROS) and play an
important role in apoptosis. In each cell, several hundreds to thou-
sands of mitochondrial DNA (mtDNA) copies are present (1,2).
mtDNA is a circular, double-stranded, 16 569 bp DNA molecule that
encodes 13 polypeptides that constitute the respiratory enzyme com-
plexes and the 22 transfer RNA and 2 ribosomal RNA genes. It is
intronless, lacks a protective histone backbone or other speciﬁc DNA-
binding proteins, replicates faster than nuclear DNA and does not
have proofreading or an efﬁcient DNA repair (3,4). mtDNA is typi-
cally located near the inner membrane of the mitochondrion and is
continually exposed to high levels of ROS and free radicals from the
electron transport chain of mitochondria. Owing to these character-
istics, mtDNA is particularly susceptible to damage by mutagens and
ROS (5,6). As a result, the mitochondrial genome exhibits 17 times
higher rates of mutation than does the nuclear genome (7), and DNA
damage persists longer in the mitochondrial genome (8,9). Thus, we
hypothesize that mtDNA damage would be a good biomarker of
tobacco smoke exposure.
Cigarette smoke is a complex mixture of .3800 compounds, in-
cluding high concentrations of both free radicals and chemical com-
pounds that readily react to form other reactive substances (10,11).
mtDNA mutations are found in tumors typically associated with
smoking, such as oropharyngeal and lung cancer (12–14). Smoking-
related damage to respiratory chain function in lymphocytes has been
correlated with measures of oxidativedamage (15). Oxidative damage
caused by smoking has also been shown to inhibit mitochondrial
enzyme activity in platelets and cause mitochondrial dysfunction in
alveolarmacrophages (16). In addition, an increase in mtDNA content
and decline in mitochondrial function also occurs in response to
DNA-damaging agents, including tobacco (12,17). Studies of lung
tissue from smokers have shown elevated measures of DNA damage
and increased DNA mutations when compared with lung tissue from
non-smokers (10,18). Taken together, these studies suggest that com-
prehensive somatic mutation screening and DNA content investiga-
tion of the mitochondrial genome may be a marker for tobacco smoke
exposure and consequently for tobacco-related DNA damage and
smoking-associated cancer risk. To the best of our knowledge, there
are no published data characterizing both somatic mutations of the
entire mitochondrial genome and also variations in mtDNA content in
the buccal cells of smokers.
Methods
Subjects and biospecimen collection
Smokers (n 5 42) were recruited via newspaper advertising for a study of
smoking behavior and health effects. Smokers must have been 18 years and
older, have smoked .10 cigarettes per day with a stable smoking pattern for
6 months, must not have had a prior history of cancer or concurrent infection
and not been on medications that would affect the immune system response.
Non-smokers (n 5 30), deﬁned as having not smoked .100 cigarettes in their
lifetime, were recruited from prostate and breast cancer screening clinics at the
Lombardi Comprehensive Cancer Center. Recruitment was done following
Institutional Review Board Approval.
Buccal cells were collected via a mouthwash protocol as published previ-
ously (19). Brieﬂy, blood was collected via standard phlebotomy procedures in
BD Vacutainer cell preparation tubes with sodium heparin (BD Vacutainer
Systems, Franklin Lakes, NJ), which allow for the separation of lymphocytes
fromotherbloodcomponents,accordingtothemanufacturer’sinstructions(20).
Isolation of DNA from lymphocytes and buccal cells
DNA was isolated from buccal cells and lymphocytes using proteinase K
(Invitrogen Corp., Carlsbad, CA) digestion and MagAttract DNA mini M48
kit in combination with the RioRobot M48 workstation (Qiagen Inc, Valencia,
Abbreviations: Co, cytochrome c oxidase; HT, heteroplasmy; HM, homo-
plasmy; mtDNA, mitochondrial DNA; PCR, polymerase chain reaction;
ROS, reactive oxygen species; TTGE, temporal temperature gradient
electrophoresis.
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Comprehensive mutational analysis of the entire mitochondrial genome
The presence of mtDNA mutations was screened by temporal temperature
gradient electrophoresis (TTGE). TTGE is based on the difference in the
sequence-speciﬁc melting behavior of normal and mutant DNA fragments that
results in different electrophoretic mobility of partially denatured mismatched
mtDNA strands. The entire 16.5 kb mtDNA genome was subjected to poly-
merase chain reaction (PCR) using 32 pairs of overlapping primers that pro-
duce amplicons varying in size from 306 to 805 bp (21,22). Each fragment has
an average of 74 bp on each end overlapping the neighboring fragments. PCR
products were denatured at 95C for 30 s and slowly cooled to 45Co v e r
a period of 45 min at a rate of 1.1C/min decrease. TTGE was performed on
a Bio-Rad D-Code mutation detection apparatus, using two back-to-back
20 cm   20 cm   1 mm 4.5–6% polyacrylamide (acrylamide:Bis 5 37.5:1)
gels in 1.25  TAE buffer containing 6 mol/l urea. Electrophoresis was carried
out at 145 V for 4–5 h at a constant temperature increment of 1–2C/h. The
beginning and ending temperatures were determined by computer simulation
fromthemeltingcurve(50%denatured)oftheDNAfragment(MacMeltsoftware,
Bio-RadLaboratories,Hercules,CA) (21–23). For TTGE analysis, a single band
shift represents a homoplasmic DNA alteration and a multiple banding pattern
representsaheteroplasmic mutation.The32mtDNAfragmentsfrombuccalcells
and lymphocytes of the same subject were analyzed side by side.
mtDNA with TTGE banding pattern abnormalities then underwent direct
DNA sequencing using the same PCR fragment; detected mutations underwent
repeat PCR and sequencing for conﬁrmation. The PCR products were puriﬁed
prior to sequencing using ExoSap-IT (USB Corp., Cleveland, OH), which
removes primers and unincorporated nucleotides. DNA sequencing was per-
formed using a DYEnamic ET terminator cycle sequencing kit (Amersham
Biosciences, Piscataway, NJ) and a MegaBACE 1000 DNA analysis system
(Amersham Biosciences). The results of DNA sequence analysis were
compared with the Human Mitochondrial DNA Revised Cambridge Reference
Sequence deposited in GenBank (accession number NC_001807) and
MitoMap (http://www.mitomap.org) using Vector NTI Advance 9 software
(InvitrogenCorp,Carlsbad,CA).AnyDNAsequencedifferencesbetweenbuccal
cells and matched lymphocytes mtDNA were scored as somatic mutations.
Detection of mtDNA deletions
The detection of two deletions of 4977 bp (np8470–8482/np13447–13459) and
4839 bp (np8703–8711/np13541–13549) was performed using PCR with four
sets of primers. During PCR, the forward primer mtF8416 (5#-CCTTACAC-
TATTCCTCATC-3#) wasused in the presenceof tworeverse primersmtR9169
(5#-TGAAAACGTAGGCTTGGAT-3#) (within the region of 4977 and 4839
bp deletions) and mtR13738 (5#-TGAGAAATCCTGCGAATAG-3#) (outside
of the 4977 and 4839 bp deletions). mtDNAwithout a deletion would serve as
a template for only the mtR8416 and mtR9196 primer sets and yield a PCR
product of 754 bp. mtDNA with the 4977 or 4839 bp deletion would serve as
a template only for the mtR8416 and mtR13738 primer sets and yield a 346 or
485 bp PCR product, respectively.
Measurement of mtDNA content (relative copy number)
An Applied Biosystems 7900 real-time PCR system was used to perform
quantitative PCR ampliﬁcation for mtDNA gene cytochrome c oxidase I (CoI).
b-actin was used as a ‘housekeeping gene’ to normalize all of the threshold
cycle (Ct) values. Primers were custom designed and obtained from Invitrogen.
CoI gene forward primer (mtCoxI-F5908), 5#-TCGCCGACCGTTGAC-
TATTCTCT-3# and reverse primer (mtCoxI-R6103), 5#-AAGATTATTAC
AAATGCATGGGC-3# (196 bp product) and b-actin forward primer, 5#-AC-
CCACACTGTGCCCATCTAC-3# and reverse primer, 5#-TCGGTGAG-
GATCTTCATGAGGTA-3# (103 bp product). Taqman probes (Applied
Biosystems, Foster City, CA) included (CoI) probe 6-FAM-AACGACCAC-
ATCTACAACGTTATCGTCAC-TAMRA and b-actin probe 6-FAM-ATG
CCCTCCCCCATGCCATCC-TAMRA (6). Real-time PCRs were performed
Table I. mtDNA mutation frequency and density by age and smoking status










d Frequency n (%) P
e
0 mutation 1 mutation 2 mutations  3 mutations
Age (years)
,45 23 9/33 (27) 0.93 0.42 ± 0.98 0.82 24 (73) 4 (12) 2 (6) 3 (9) 0.90
 45 34 11/39 (28) 0.52 ± 1.07 28 (72) 3 (8) 3 (8) 5 (13)
Gender
Female 20 7/36 (19) 0.11 0.35 ± 0.88 0.20 29 (81) 2 (6) 3 (8) 2 (6) 0.25
Male 37 13/36 (36) 0.62 ± 1.14 23 (64) 5 (14) 2 (6) 6 (17)
Race
Caucasian 29 12/46 (26) 0.67 0.38 ± 0.88 0.54 34 (78) 5 (11) 3 (7) 4 (9) 0.83
AA
f and Asian 28 8/28 (28) 0.65 ± 1.23 18 (64) 2 (7) 2 (7) 4 (14)
Smoking status
Non-smoker 10 7/30 (23) 0.48 0.20 ± 0.40 0.05
g 23 (77) 4 (13) 3 (10) 0 (0) 0.04
Smoker 47 13/42 (31) 0.68 ± 1.27 29 (69) 3 (7) 2 (5) 8 (19)
Pack-years
5–18.9 15 5/14 (36) 0.76 0.65 ± 1.15 0.60 9 (64) 2 (14) 0 (0) 3 (21) 0.62
19–36.9 11 3/13 (23) 0.51 ± 1.35 10 (77) 1 (8) 1 (8) 1 (8)
.37 21 5/15 (33) 0.85 ± 1.37 10 (67) 0 (0) 1 (7) 4 (27)
Age at smoking initiation
,17 24 8/22 (36) 0.51 0.66 ± 1.28 0.66 14 (64) 3 (14) 2 (9) 3 (14) 0.16
 17 23 5/20 (25) 0.69 ± 1.29 15 (75) 0 (0) 0 (0) 5 (25)
Years smoked
5–19 10 3/13 (23) 0.54 0.46 ± 1.33 0.36 10 (77) 2 (15) 0 (0) 1 (8) 0.55
20–37 25 7/17 (41) 0.88 ± 1.30 10 (59) 1 (6) 1 (6) 5 (29)
.38 12 3/12 (25) 0.60 ± 1.21 9 (75) 0 (0) 1 (8) 2 (17)
Cigarettes smoked
per day
10–15 20 6/15 (40) 0.49 0.81 ± 1.20 0.27 9 (60) 1 (7) 1 (7) 4 (27) 0.4
16–24 10 4/19 (21) 0.32 ± 0.86 15 (79) 2 (11) 1 (5) 1 (5)
.25 17 3/8 (38) 1.28 ± 1.95 5 (63) 0 (0) 0 (0) 3 (38)
aMutation frequency: number of subjects with mutations/total number of subjects (%).
bChi-square test.




gMean difference in mutation density between smokers and non-smokers 0.47 ± 0.40 (mean ± SD).
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1  TaqMan Universal PCR Master Mix (Applied Biosystems), 900 nM of
each primer, 200 nM of eachTaqMan probe and 5 ng of total genomic DNA.
Thermal cycling conditions were an initial 2 min at 50C and 10 min at 95C,
followed by 45 cycles of 15 s of denaturation at 95C and 60 s of annealing/
extension at 60C. Fluorescent signal intensity was recorded and analyzed using
SDS version 2.1 software (Applied Biosystems). The Ct value within the linear
exponential increase phase was used to measure the original copy number of the
DNAtemplate.Anaverage b-actin Ct valuewaschosenasa normalizationvalue.
The correction Ct value for b-actin and CoI as well as the relative number of
mtDNA copies were calculated using the following equations, respectively: b-
actin correction value 5 mean sample Ct b-actin value   20 and the corrected
CoI Ct value 5 meanCoI Ct   b-actin correctionvalue.The maximum normal-
ized Ct value of all samples was determined to equal one copy of CoI, and the
relative Cox copy number 5 2(maximum C
t
  corrected CoI C
t
value). The mtDNA
content was expressed as the ratio of CoI I copy number to b-actin gene copy
number.
Statistical analysis
Pack-years were calculated as usual packs of cigarettes smoked per day mul-
tiplied by years of smoking. Subjects were classiﬁed into smoking and age
categories by the median and tertiles, as indicated in Tables I and IV. Fisher’s
exact test, chi-square test and Wilcoxon rank test were used to analyze the
association between mtDNA mutations and cigarette smoking status. The
t-test, paired t-test and analysis of variance test were used to analyze the
difference in mutation density and mtDNA content between smokers and
non-smokers. The probability of the trend for increased mutation frequency
in relation to smoking status was tested by the Cochran–Armitage test. The
correlation between mtDNA mutation density, relative content and smoking
status was analyzed by the non-parametric Spearman’s rho correlation test and
the Pearson’s correlation test after log transformation of the data. P values
,0.05 are considered statistically signiﬁcant. All statistical computations were
done using the SPSS v14.0 (SPSS, Chicago, IL) and SAS v9.12 (SAS Institute,
Cary, NC). All reported P values are two sided.
Results
Subjects’ age ranged from 19 to 87 years with a mean age of 45.4 ±
13.4 for smokers and 45.8 ± 14.5 for non-smokers. Among smokers,
there were 22 men and 20 women, 29 were Caucasians and 13 were
African-Americans. Among non-smokers, there were 14 men and 16
women. Seventeen were Caucasians and 13 were African-Americans
or Asians.
mtDNA somatic mutations analysis
Somatic mtDNA mutations in buccal cells from 42 smokers and
30 non-smokers were detected by parallel analysis using TTGE and
direct sequencing. Sequence patterns that were different comparing
buccal cells with lymphocytes were considered to represent acquired
mutations in the buccal cells (Figure 1). The mtDNA mutation fre-
quency and density by age and smoking status is shown in Table I.
There was no correlation found between mutation density and age
among all subjects (P 5 0.58), smokers (P 5 0.79) or non-smokers
(P 5 0.47). The frequency of mutations, mutation density and type of
mutation also did not differ by gender or race.
Table II provides summary data for mtDNA mutations and Table III
lists all mutations found in all subjects. Among smokers, 31% (13/42)
harbored at least one mutation with a total of 39 point mutations and 8
short deletions/insertions detected. In contrast, only 23% (7/30) of
non-smokers possessed mutations with a total of 10 point mutations
and no deletions/insertions. Although there was no signiﬁcant differ-
ence in mutation incidence detected between these two groups
(P 5 0.48), mtDNA somatic mutation density, deﬁned as somatic
mutation number/10000 bp per person, was statistically higher in
smokers (0.68) than in non-smokers (0.20) on average. The mean
difference was 0.47 ± 0.40 (P 5 0.05, Table I). In smokers, most
mutations were spread across the entire mtDNA genome, whereas
non-smokers had most of their mutations in the D-loop region. For
example, only 10% of non-smokers had mutations in the messenger
RNA-encoding region, whereas 36% smokers had mutations in that
region. About 49% of smokers had mutations in the D-loop region,
whereas 70% of non-smokers had mutations in the D-loop region
(P 5 0.10, Fisher’s exact test, Table II). In addition, eight short dele-
tions/insertions were found in 19% of smokers, which represents 17%
of all somatic mutations detected. We found four deletion/insertions
of C or CC at nucleotide position 303–309 mononucleotide
repeat (poly-C) region, three single nucleotide deletion/insertions
(7447–7452 del A, 7466–7471 ins C and 15940–15944 del T) in
transfer RNA serine and threonine and one deletion/insertion in the
cytochrome c oxidase subunit I (7397–7402 ins C) that results in
a frameshift and a truncated polypeptide of 510 amino acid residues.
There were 17 point mutations located in the messenger RNA region.
Among them, 44% were missense mutations. Twelve of 39 (31%)
distinct somatic mutations found in smokers have not been reported
previously in the Mitomap database; 27 (69%) of these occur in germ
line polymorphic sites.
The incidence rate of heteroplasmy (HT) and homoplasmy (HM) of
mtDNA somatic mutations, comparing buccal cells with lymphocytes,
were different between smokers and non-smokers. The most prevalent
mutation pattern found in smokers was HM / HM. The frequency of
each offour patterns HM / HM, HM / HT, HT / HM and HT /
HT was 55, 30, 13 and 2% in smokers, whereas it was 20, 70, 0 and
10% in non-smokers, respectively (P 5 0.04, Table II).
Among smokers, there was no signiﬁcant difference in mtDNA
mutation frequency for pack-years (P 5 0.76), number of cigarettes
smoked per day (P 5 0.49), years smoked (P 5 0.54) and age at
smoking initiation (P 5 0.51). The relationship between mtDNA mu-
tation status and smoking is summarized in Table I. The incidence of
multiple mutations is signiﬁcantly higher in heavy smokers than in
non-smokers (P 5 0.045). Heavy smokers had greater numbers of
mutations than lighter smokers, but the trend was not statistically
signiﬁcant (P 5 0.10).
mtDNA content and large-scale deletions
mtDNA content was measured by calculating the ratio of relative copy
number of the CoI gene to b-actin. There was no relationship between
mtDNA content and age, gender or race (Table IV).
Table II. Summary of mtDNA mutations in smokers and non-smokers






with mutations, n (%)





mRNA 1 (10) 17 (36) 0.10
tRNA 0 (0) 5 (11)
rRNA 2 (20) 2 (4)
D-loop and non-coding area 7 (70) 23 (49)
Homoplasmic/heteroplasmic patterns, n (%)
HM / HM 2 (20) 26 (55) 0.04
HM / HT 7 (70) 14 (30)
HT / HM 0 (0) 6 (13)
HT / HT 1 (10) 1 (2)
Mutation type, n (%)
Short deletion
or insertion
0 (0) 8 (17) 0.33
Point mutation 10 (100) 39 (83)
Transition 9 (90) 37 (95) 0.50
Tranversion 1 (10) 2 (5)
Type of mRNA mutations
Missense mutation 0 (0) 7 (44) 1.00
Silent mutation 1 (100) 9 (56)
mRNA, messenger RNA; tRNA, transfer RNA; rRNA, ribosomal RNA.
aTwo-sided Fisher’s exact test.
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b Function location,







2444 1 A 100 A/C C/A HT / HT A2444C rRNA 16S Novel
2706 1 A 19.5 A G HM / HM A2706G rRNA 16S SNP site,
oral cancer
10115 1 T 97.7 C T HM / HM C10115T mRNA ND3, ATC / ATT, I19I SNP site,
lung cancer
16223 3 C 53.0 T T/C HM / HT T16223C D-loop HVS1, 7S DNA SNP site,
oral cancer
16278 4 C 93.1 C T/C HM / HT C16278T D-loop HVS1, 7S DNA Oral cancer
Smoker
303 4 7C 91.9 7C 8C HM/HT / HM/HT 303–309 ins C D-loop TFY, CSB2, OH, HVS2 SNP site,
esophageal, ovarian
and oral cancer
322 1 G 99.8 G/A G HT / HM A322G D-loop OH, HVS2 Novel
930 1 G 97.8 G/A A HT / HM G930A rRNA 12S SNP site
936 1 G 100 G/A A HT / HM G936A rRNA 12S Novel
4529 1 A 98.7 T A HM / HM T4529A mRNA ND2, ACT / ACA, T20T SNP site
7315 1 T 100/55.6 T/C T/C HT / HT T7315C mRNA CoI, ATG / ACT, M471T Novel
7397 1 6C 100 5C 6C HM / HM 7397–7402 ins C mRNA CoI Novel
7409 1 C 100/66.7 C C/A HM / HT C7409A mRNA CoI, TAC / TAA, Y502T Novel
7447 1 6A 100 6A 5A HM / HM 7447–7452 del A tRNA serine 1 Novel
7466 1 6C 100 6C/5C 6C HT / HM 7466–7471 ins C tRNA serine 1 Novel
7951 1 A 99.9 A G HM / HM A7951G mRNA CoII, ATA / ATG, M122M Novel
9947 1 G 99.5 G A HM / HM G9947A mRNA CoIII, GTG / GTA, V247V SNP site
10034 2 T 98.6 T C HM / HM T10034C tRNA glycine SNP site
10086 1 A 99/,20 A/G G HT / HM A10086G mRNA ND3, AAC / GAC, N10D SNP site
10115 1 T 97.7 T C HM / HM T10115C mRNA ND3, ATT / ATC, I19I SNP site,
lung cancer
10238 1 T 96.9 C T HM / HM C10238T mRNA ND3, ATC / ATT, I60I SNP site
10373 1 G 99 G A HM / HM G10373A mRNA ND3, GAG / GAA, E105E SNP site
10398 1 A 54.2/44.4 A G HM / HM A10398G mRNA ND3, ACC / GCC, T114A SNP site
10530 1 G 99.9/22.2 G A HM / HM G10530A mRNA ND4L, GTA / ATA, V21M Novel
13105 1 A 94.9/55.6 G A HM / HM G13105A mRNA ND5, GTC / ATC, V257I SNP site
13563 1 A 98.6 A G HM / HM A13563G mRNA ND5, CTA / CTG, L409L SNP site
13590 1 G 95.9 G A HM / HM G13590A mRNA ND5, CTG / CTA, L418L SNP site
13650 1 C 94.3 C T HM / HM C13650T mRNA ND5, CCC / CCT, P438P SNP site
15824 1 A 99.3/,20 A G HM / HM A15824G mRNA Cytb, ACA / GCA, T360A Novel
15940 1 5T 100 5T 4T HM / HM 15940–15944 del T tRNA threonine Novel
16153 1 G 99.4 G A HM / HM G16153A mRNA HVS1, 7S DNA SNP site
16179 1 C 99.7 T C HM / HM T16179C D-loop HVS1, 7S DNA SNP site
16220 1 A 99.9 A C HM / HM A16220C D-loop HVS1, 7S DNA SNP site
16223 2 C 53.0 T C/T HM / HT T16560C D-loop HVS1, 7S DNA Novel
16255 1 G 99.6 A G/A HM / HT A16255G D-loop HVS1, 7S DNA SNP site
16256 1 C 98.5 T C/T HM / HT T16256C D-loop HVS1, 7S DNA SNP site,
oral cancer
16265 1 A 98.6 A G/A HM / HT A16265G D-loop HVS1, 7S DNA SNP site
16270 1 C 96.4 T C/T HM / HT T16270C D-loop HVS1, 7S DNA SNP site,
oral cancer
16278 3 C 93.1 C T/C HM / HT/HM C16278T D-loop HVS1, 7S DNA SNP site,
oral cancer
16294 1 C 93.9 C T HM / HM C16294T D-loop HVS1, 7S DNA SNP site,
oral cancer
16298 1 T 90.4 T C/T HM / HT T26298C D-loop HVS1, 7S DNA SNP site,
oral cancer
16362 2 T 75.2 T C/T HM / HT T16362C D-loop HVS1, 7S DNA SNP site,
oral cancer
16384 1 G 100 G G/A HM / HT G16384A D-loop 7S DNA SNP site
16390 1 G 97 A G/A HM / HT A16390G D-loop 7S DNA SNP site,
oral cancer
NP, nucleotide position; Lym, lymphocytes; Buc, buccal cells; AA, amino acid; SNP, single-nucleotide polymorphism; TFY, mtTF1-binding site; OH, H-strand
origin; HVS, hypervariable segment; Co, cytochrome c oxidase subunit; ND, nicotinamide adenine dinucleotide(H) dehydrogenase subunit.
aPF, polymorphism frequency of Cambridge sequence at this position in Human Mitochondrial Genome Database (mtDB, http://www.genpat.uu.se/mtDB/); IR,
identical rate in evolution conservation: identical 100%. The sequences from multiple phyla including human, gorilla, bovine, mouse, chicken, frog, ﬂy, and urchin
were used for evolution conservation analysis. conserved .70%, similar 20–70%, non-similar ,20%; evolution conserved analysis (consensus calculation) was
made by Vector NTI 9.0 (Invitrogen).
bMissense mutation, deletion and insertion are in bold.
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signiﬁcantly higher in smokers (2.81) than in non-smokers (0.46,
P 5 0.004, Table IV). The mean mtDNA content in the buccal cells
of smokers increased 1.6 times relative to non-smokers. Although the
relative mean mtDNA content in lymphocytes was signiﬁcantly high-
er than in buccal cells for non-smokers (P , 0.001, paired t-test), no
signiﬁcant difference was detected in smokers. We also investigated
the relationship of mutation frequency and density to mtDNA content.
There was no signiﬁcant correlation between mutation density and
content of mtDNA (P 5 0.76 for buccal cells and P 5 0.75 for lym-
phocytes). In addition, a low positive correlation between ratio of
buccal cells/lymphocytes mtDNA content and smoking status has
Table IV. The ratio of CoI/b-actin and ratio of buccal cells/lymphocytes (mean ± SD)
Total numbers CoI/b-actin in
buccal cells
P value CoI/b-actin in
lymphocytes




Non-smoker 30 247.88 ± 239.59 0.28 613.00 ± 362.54 0.01 0.46 ± 0.39 0.004
Smoker 42 398.70 ± 586.01 505.72 ± 693.13 2.81 ± 6.22
Pack-years
5–18.9 14 447.69 ± 722.73 0.59 318.21 ± 192.77 0.73 2.69 ± 4.39 0.81
19–36.9 13 259.80 ± 296.83 687.85 ± 980.40 4.09 ± 9.99
 37 15 473.35 ± 647.19 522.87 ± 521.17 1.80 ± 2.73
Age at smoking initiation
,17 22 390.66 ± 606.19 0.46 340.48 ± 416.56 0.01 3.98 ± 8.17 0.15
 17 20 407.54 ± 578.56 687.49 ± 789.48 1.60 ± 2.47
Years smoked
5–19 13 435.62 ± 737.06 0.96 322.71 ± 226.70 0.19 4.92 ± 9.69 0.47
20–37 17 415.29 ± 629.88 619.70 ± 571.57 1.45 ± 3.79
 38 12 335.20 ± 322.21 542.51 ± 964.43 1.86 ± 2.26
Cigarettes smoked
per day
10–15 15 280.25 ± 279.87 0.27 542.42 ± 842.46 0.9 4.92 ± 9.69 0.35
16–24 19 487.91 ± 830.50 479.88 ± 546.17 1.45 ± 2.79
 25 8 408.93 ± 171.33 498.27 ± 448.60 1.86 ± 2.26
All P values are from t-test or analysis of variance performed on log-transformed observations.
Fig. 1. Four representative somatic mutation sequences at different mtDNA regions in smokers. (A) Heteroplasmic to homoplasmic insertion of cytidine at
np7466–7471 transfer RNA (tRNA) serine 1; (B) HM to HM change of T10034C at tRNA glycine; (C) Heteroplasmic to homoplasmic deletion C at poly-(C)n
tract D310 of D-loop region and (D) HM to HM transversion change of C7409A at cytochrome c oxidase subunit I of messenger RNA coding region.
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r 5 0.27, P 5 0.02 for age at smoking initiation and r 5 0.36,
P 5 0.02 for cigarettes smoked per day).
Large4977bpmutationsarefrequentlyreportedasageing-associated
molecular events (24). A high frequency of 4839 bp deletion of
mtDNA was found in smokers with lung cancer (10). In our study,
the large 4977 bp common deletion was detected in 4.8% of smokers
and 3.3% of non-smokers. No 4839 bp deletions were found in either
smokers or non-smokers. There was no difference in frequencies by
age, gender race or smoking status (data not shown). There also was
no difference by pack-years, age at initiation, number of years of
smoking or cigarettes per day (data not shown).
Discussion
There are no validated smoking-related biomarkers for cancer risk,
although some exist for smoke exposure (25). To date, there has been
little research directed toward the study of mtDNA as a biomarker for
smoke exposure or tobacco-related disease risk. In this study, we
found that buccal cells of healthy smokers harbored both a higher
mtDNA mutation frequency and mutation density, relative to non-
smokers. The type of mitochondrial mutations was different for smok-
ers and non-smokers.
There are several reasons why mtDNA analyses could be a useful
biomarker for tobacco smoke exposure. It is known that mtDNA is
highly prone to oxidative damage as it is in close contact with the ROS
produced in the mitochondria (3,26,27). Also, lipids within the mito-
chondrial membrane and lipid peroxidation have been shown to be
one potential source of continued DNA damage. Secondary ROS
reactions have the potential of overwhelming the repair capacity of
the mitochondrion, which already functions with limited capacity, and
can lead to persistent DNA damage (28). The mtDNA mutation rate is
10–100 times higher than that of nuclear DNA. The vulnerability of
the mitochondrial genome to oxidative damage could be due to many
factors including: (i) the absence of histones or DNA-binding pro-
teins; (ii) a limited basic repair mechanism; (iii) genes consisting only
of exons without introns and (iv) replicating rapidly without a signif-
icant proofreading system.
In this study, we consider buccal cells as an easily accessible tissue
for biomarker studies in smokers and a target organ for smoking-
related cancer. Previous studies have shown that smoking is associ-
ated with increased mtDNA content in a dose-dependent fashion (6).
mtDNA alterations in response to smoking persist for several decades
after smoking cessation, consistent with long-term smoking-related
damage (6). However, we are not aware of published data for mtDNA
mutations in buccal cells by smoking status. Studies have shown that
normal lung tissue of smokers have more mtDNA mutations by age
and smoking history (10,18,29). Smoking also increases the fre-
quency of mtDNA deletions in lung tissues, and the incidence and
proportion in current smokers were signiﬁcantly higher than in those
of non-smokers (10). Tobacco smoke exposure has been shown to
induce mitochondrial damage and depolarization, as well as mtDNA
damage, incardiovascular tissue(30).Inthisreport,wepresentacom-
prehensive study of both mtDNA somatic mutations and copy number
in buccal cells of smokers and non-smokers. The results show that
31% (13/42) of smokers harbored somatic mtDNA mutations com-
pared with 23% of non-smokers. While this difference was not statis-
tically signiﬁcant, a larger study might have revealed a statisticial
difference. This percentage of mutations is higher than prior reports
for betel quid chewers, who have a mutation rate of 10% (31). About
1.5% of human bronchial epithelium colonies contained hundreds or
even thousands of homoplasmic mutant cells (32). Our results show
that the mutation density in smoker increases with smoking. The
results herein reﬂect, to a certain extent, the relationship between
smoking and cancer. Lung cancers have a mutation rate of 47%
(33) and oral cancers have a rate of 78% (14). In this study, nine
(33%) of the identiﬁed somatic mutations have been reported pre-
viously as somatic mutations in smoking-related oral or lung cancer,
but have not been found in other mitochondrial diseases or other
tumors (21,33–37).
In this study, 17% of smokers had a mtDNA length alteration in
their buccal cells and the insertion or deletion (C7-.8/9 or C8/9-.7)
of poly-(C)n tract 303–309 has been found in four (9%). This has not
been reported previously for normal tissues, but can occur in 21–72%
of breast, oral and prostate cancers (12,14,21,35,36,38). The mono-
nucleotide repeats between nucleotides 303 and 309 are among the
Fig. 2. Correlations between ratio of buccal cells/lymphocytes mtDNA content and smoking status. Pearson’s correlation test (two tailed) after data log
transformation.
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meric C stretch is part of the conserved sequence block II located
within the regulatory D-loop region and is involved in the formation
of a persistent RNA–DNA hybrid that leads to the initiation of
mtDNA heavy-strand replication (39). The alteration rate in this area
is sequence dependent (40). That is, if the sequence has 7 C repeats, it
will be stable and so is less prone to frameshift mutations. The re-
maining four single-base deletions in this study occurred in the trans-
fer RNA and messenger RNA regions, which can lead to
mitochondrial dysfunction, increase ROS production and promote
aberrant cell proliferation. It is also interesting to note that both
homoplasmic and heteroplasmic mutations occur. Unlike in non-
smokers, more than half of the mutations found in smokers are ho-
moplasmic, indicating that cigarette smoke may accelerate the shift-
ing process from heteroplasmic to homoplasmic mutation or these
mutation sites are sensitive to the attack of mutagens.
Althoughitisdifﬁculttopredictthepathogenicroleofspeciﬁcmuta-
tions in smokers, some of the mutations we detected were located in
structurally and/or functionally important regions. Several would alter
proteinsequence and structure, e.g. a missense mutation G10530A that
would replace a valine with methionione in the nicotinamide adenine
dinucleotide (H) dehydrogenase subunit 4L or others at C7409A
(Y502T), T7315C (M471T), G13105A (V257I), G10530A (V21M)
and A15824G (T360A). Whether mtDNA mutations are markers for
morphologically normal cells that will transform to cancer can only be
determined from prospective studies. Tumor cells containing a mtDNA
mutation grow faster than cells with identical nuclei and unmutated
mitochondria (36), so mtDNA mutations in buccal cells of smokers
without cancer might reﬂect an early carcinogenic process.
While DNA damage to nuclear DNA actively promotes the carci-
nogenic process, the role of mtDNA mutations might also be impor-
tant. A recent study in 202 non-small cell lung cancer patients found
that 70 patients (35%) had various mutations in the D-loop region of
mtDNA in cancer cells with mutations at 16117A / T and 16368
A /T being the most prevalent. The D-loop region mutation rate of
non-small cell lung cancer patients in stage IIIB or higher as well as
T3 stage of tumor-node-metastasis factors was signiﬁcantly greater
than in other patients (13). In addition, three mutation hot spots were
observed in the D-loop at nucleotides 146, 152 and 186 in oral squa-
mous cell carcinomas (12). Other studies also have shown that homo-
plasmic and heteroplasmic mutations occur in 47–78% cases of lung
and oral cancers (12,14,33,41). These somatic mutations range from
severe insertion–deletion and chain termination mutations to mild
missense mutations. Mutations anywhere in the mtDNA might have
an adverse effect because the entire mtDNA genome is expressed and
continuously replicated. Thus, mutations might cause a decreased
capacity for apoptosis and increased production of free radicals. For
example, severe mutations may inhibit oxidative phosphorylation,
increase ROS production and promote tumor cell proliferation,
whereas milder mutations may permit tumors to adapt to new environ-
ments. Hence, mitochondrial dysfunction does appear to be a factor in
cancer etiology, an insight that may suggest new approaches for di-
agnosis and treatment.
Some studies have shown that an increase in mtDNA content is
associated with DNA damage and reduced respiratory chain function
secondary to oxidative damage (34). As described above, smoking is
associated with increased mtDNA copy number among 42 smokers,
dose dependently. In our study, mtDNA copy number increased up to
1.6-fold (61% increase), whereas Masayesva et al. (6) reported a 31%
increase. The reasons for increased mtDNA copy number are unclear,
but one hypothesis is that increasing copy number may be a compen-
satory mechanism in response to oxidative damage induced by ciga-
rette smoke (6). This hypothesis is consistent with observations that
decreased energy production from damaged mitochondria induces
nuclear signals leading to compensatory replication (1,6,36). We also
found that mtDNA content of lymphocytes is higher than that of
buccal cells of both smokers and non-smokers. This might be due
to differences in cell proliferation rates or cellular energy require-
ments and metabolism.
Our results demonstrate that cigarette smoking increases mtDNA
mutations and copy number in the buccal cells of smokers. Although
some of these mutations are located in structurally/functionally im-
portant regions and may affect the biogenesis of mitochondria, no
single mutational hot spot or signature was found. This study did
not investigate the biopersistence of biomarkers, and so it is unknown
if these ﬁndings reﬂect recent or long-term exposure, although the
data showing correlations with cigarettes per day and not years smok-
ing suggests the former. This study did not address the half-life of the
markers, which can only be done with a smoking cessation study. In
addition, we did not evaluate the possibility of the presence of leuko-
cyte in the mouthwash. Although it is possible that oral cells might be
a mix of epithelial cell and other cells, we were able to detect the
somatic changes in mitochondrial genome between oral cells and
blood lymphocytes. Further research will be needed to determine if
mtDNA analysis has the speciﬁcity for detecting changes in smoke
exposure or if the estimation of an individual’s risk could be improved
by coupling of mitochondrial mutations to other markers for tobacco
smoke-associated disease risk or smoking-related harm. Also, the data
presented here provide justiﬁcation for the development of eco-
nomically feasible high-throughput methods for detecting mtDNA
mutations.
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